Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 35718 Insp IMP 35718/876362-0015[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER*(1),(2)*

Part 1

Issued following an inspection in accordance with :
Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : QUOTIENT SCIENCES LIMITED

Site address : QUOTIENT SCIENCES LIMITED, 5 BOULTON ROAD, READING, RG2 0NH, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 35718 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 04/02/2022 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- *(1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.*
- *(2) These requirements fulfil the GMP recommendations of WHO.*

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.2] Non-sterile investigational medicinal products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.1] Capsules, hard shell

[1.2.1.5] Liquids for external use

[1.2.1.6] Liquids for internal use

[1.2.1.8] Other solid dosage forms

[1.2.1.9] Pressurised preparations

[1.2.1.11] Semi-solids

[1.2.1.12] Suppositories

[1.2.1.13] Tablets

[1.2.1.17] Other non-sterile medicinal products
Blister/Multidose Resovoir Dry Powder Inhaler,DPI/PMDI

[1.2.2] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.5] Biotechnology products

[1.4] Other products or manufacturing activity

[1.4.1] Manufacture of:

[1.4.1.1] Herbal products

[1.4.1.3] Other
Traditional Herbal Medicines/Importation of QP-certified IMPs from a country on the approved countr

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.1] Capsules, hard shell

[1.5.1.2] Capsules, soft shell

[1.5.1.8] Other solid dosage forms

[1.5.1.9] Pressurised preparations

[1.5.1.11] Semi-solids

[1.5.1.12] Suppositories

[1.5.1.13] Tablets

[1.5.1.14] Transdermal patches

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.3] Chemical/Physical

[1.6.4] Biological

2. IMPORTATION OF MEDICINAL PRODUCTS

MHRA-GMDP MHRA-GMDP MHRA

[2.2] Batch certification of imported medicinal products

[2.2.1] Sterile Products

[2.2.1.1] Aseptically prepared

[2.2.1.2] Terminally sterilised

[2.2.2] Non-sterile products

[2.3] Other Importation Activities

[2.3.1] Site of Physical Importation

[2.3.4] Other

Traditional Herbal Medicines/Importation of QP-certified IMPs from a country on the approved countr

Restrictions or Remarks

This was a focused remote inspection following a variation to add import oversight for IMP from listed countries.

14/02/2022	Name and signature of the authorised person of the Competent Authority of United Kingdom Confidential Medicines and Healthcare products Regulatory Agency Tel : Confidential

MHRA-GMDP